Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
Fukuda T, Yamazaki H, Miyatani Y, Sawada T, Shibuya N, Fukuo Y, Kiyohara H, Morikubo H, Tominaga K, Kakimoto K, Imai T, Yaguchi K, Yamamoto S, Ando K, Nishimata N, Yoshihara T, Andoh A, Hibi T, Matsuoka K; IBD Terakoya Group. Fukuda T, et al. Among authors: kiyohara h. Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18013. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38651779
Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Sagami S, et al. Among authors: kiyohara h. Aliment Pharmacol Ther. 2022 May;55(10):1320-1329. doi: 10.1111/apt.16817. Epub 2022 Feb 25. Aliment Pharmacol Ther. 2022. PMID: 35218038
Immunomodulators after the discontinuation of anti-tumor necrosis factor-alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study.
Asonuma K, Ozeki K, Yamazaki H, Okabayashi S, Okano S, Ozaki R, Nishimata N, Kiyohara H, Ichinari N, Kobayashi T, Yamada M, Matsubayashi M, Yokoyama Y, Arimitsu S, Umeno J, Munetomo Y, Andoh A, Shinzaki S; IBD Terakoya Group. Asonuma K, et al. Among authors: kiyohara h. J Gastroenterol Hepatol. 2024 Jan;39(1):66-73. doi: 10.1111/jgh.16376. Epub 2023 Oct 12. J Gastroenterol Hepatol. 2024. PMID: 37823425
Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition.
Morikubo H, Kobayashi T, Ozaki R, Okabayashi S, Kuronuma S, Takeuchi O, Shiba T, Kiyohara H, Matsubayashi M, Sagami S, Nakano M, Ikezaki O, Hisamatsu T, Tanaka Y, Hibi T. Morikubo H, et al. Among authors: kiyohara h. J Gastroenterol Hepatol. 2021 Aug;36(8):2116-2124. doi: 10.1111/jgh.15411. Epub 2021 Jan 29. J Gastroenterol Hepatol. 2021. PMID: 33470487
Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T. Saigusa K, et al. Among authors: kiyohara h. Dig Endosc. 2016 Sep;28(6):665-70. doi: 10.1111/den.12655. Epub 2016 Apr 21. Dig Endosc. 2016. PMID: 26997640
The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission.
Arai M, Naganuma M, Sugimoto S, Kiyohara H, Ono K, Mori K, Saigusa K, Nanki K, Mutaguchi M, Mizuno S, Bessho R, Nakazato Y, Hosoe N, Matsuoka K, Inoue N, Ogata H, Iwao Y, Kanai T. Arai M, et al. Among authors: kiyohara h. J Crohns Colitis. 2016 Nov;10(11):1303-1309. doi: 10.1093/ecco-jcc/jjw104. Epub 2016 May 18. J Crohns Colitis. 2016. PMID: 27194529
361 results